This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. Today, we’re offering insight into the latest numbers from Amgen, Pfizer and Merck & Co. A blemish on Amgen’s ‘high quality’ quarter Over the course of last year, Amgen recorded $35.1 billion in annual product sales, ...